Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN5459 · 1 trial · 2 indications
Phase 1
Phase 1
Phase 1
Phase 2
| Arm | Type | Description |
|---|---|---|
| REGN5459 | EXPERIMENTAL | Cohorts of multiple REGN5459 dose levels |
| Name | Type | Description |
|---|---|---|
| REGN5459 | DRUG | Administered by intravenous (IV) infusion |
Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status ≤1 * Patients must have myeloma that is response-evaluable according to the 2016 International Myeloma Working Group (IMWG) response criteria * Measurable disease is defined as 1 or more of the following: 1. S...
Top 20 of 25 competitors
REGN5459 is an investigational small molecule being developed for the treatment of relapsed multiple myeloma. It is intended for adult patients with relapsed or refractory multiple myeloma, a type of blood cancer that has not responded to or has returned after prior treatment.
REGN5459 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol REGN. The company conducted a first-in-human study of the drug in the United States.
REGN5459 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in clinical trials.
REGN5459 has been studied in one clinical trial, identified as NCT04083534. This was a first-in-human, Phase 1 study in adult patients with relapsed or refractory multiple myeloma. The trial was conducted in the United States and enrolled 43 participants.
REGN5459 is a distinct investigational drug candidate developed by Regeneron Pharmaceuticals. It is not known by any other names, and it is not the same as other approved or investigational therapies for multiple myeloma.